Transfection of the SSO in Down Syndrome (DS) patient-derived fibroblasts, leads to a dose-dependent decrease of full-length APP and results in reduced and normalised levels of the Aβ42 peptide (Chang et al., 2018). This evidence concerns the gene APP and Down syndrome.